Lena Sellman - Associate Director, Head of Regulatory Affairs Sweden - Teva Pharmaceuticals (Teva Sweden AB) | LinkedIn
![PDF) Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler PDF) Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler](https://i1.rgstatic.net/publication/277779575_Effect_of_inhalation_profile_and_throat_geometry_on_predicted_lung_deposition_of_budesonide_and_formoterol_BF_in_COPD_An_in-vitro_comparison_of_Spiromax_with_Turbuhaler/links/5674822e08aebcdda0de260d/largepreview.png)
PDF) Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler
![Independent Identification of Handling Errors for Dry Powder Inhalers, Spiromax® and Turbuhaler®, Using a Delphi Process Involving Respiratory Device Experts | SpringerLink Independent Identification of Handling Errors for Dry Powder Inhalers, Spiromax® and Turbuhaler®, Using a Delphi Process Involving Respiratory Device Experts | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41030-015-0008-5/MediaObjects/41030_2015_8_Fig1_HTML.gif)